Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 01 2020
15 01 2020
Historique:
received:
24
09
2019
accepted:
16
12
2019
entrez:
17
1
2020
pubmed:
17
1
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that may lead to liver cirrhosis or hepatocellular carcinoma. Here, we examined the diagnostic utility of tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin (AAT-A3F), a non-invasive glycobiomarker identified in a previous study of NASH diagnosis. This study included 131 biopsy-proven Japanese patients with NAFLD. We evaluated the utility of AAT-A3F in NASH diagnosis, and conducted genetic analysis to analyse the mechanism of AAT-A3F elevation in NASH. Serum AAT-A3F concentrations were significantly higher in NASH patients than in NAFL patients, and in patients with fibrosis, lobular inflammation, and ballooning. Hepatic FUT6 gene expression was significantly higher in NASH than in NAFL. IL-6 expression levels were significantly higher in NASH than in NAFL and showed a positive correlation with FUT6 expression levels. The serum-AAT-A3F levels strongly correlated with hepatic FUT6 expression levels. AAT-A3F levels increased with fibrosis, pathological inflammation, and ballooning in patients with NAFLD and may be useful for non-invasive diagnosis of NASH from the early stages of fibrosis.
Identifiants
pubmed: 31941930
doi: 10.1038/s41598-019-56947-1
pii: 10.1038/s41598-019-56947-1
pmc: PMC6962197
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
Polysaccharides
0
SERPINA1 protein, human
0
alpha 1-Antitrypsin
0
Fucosyltransferases
EC 2.4.1.-
FUT6 protein, human
EC 2.4.1.65
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
321Références
Ratziu, V. et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372–384 (2010).
doi: 10.1016/j.jhep.2010.04.008
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64, 73–84 (2016).
doi: 10.1002/hep.28431
Sayiner, M. et al. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin. Liver Dis. 20, 205–214 (2016).
doi: 10.1016/j.cld.2015.10.001
Rafiq, N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234–238 (2009).
doi: 10.1016/j.cgh.2008.11.005
Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).
doi: 10.1056/NEJMra011775
Cadranel, J. F., Rufat, P. & Degos, F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 32, 477–481 (2000).
doi: 10.1053/jhep.2000.16602
Froehlich, F., Lamy, O., Fried, M. & Gonvers, J. J. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig. Dis. Sci. 38, 1480–1484 (1993).
doi: 10.1007/BF01308607
Wieckowska, A. & Feldstein, A. E. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 28, 386–395 (2008).
doi: 10.1055/s-0028-1091983
Velan, B. et al. N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis. Biochem. J. 296, 649–656 (1993).
doi: 10.1042/bj2960649
Klein, A., Michalski, J. C. & Morelle, W. Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, is it all about immunoglobulins? Proteomics Clin. Appl. 4, 372–378 (2010).
doi: 10.1002/prca.200900151
Zhu, J. et al. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J. Proteome. Res. 13, 2986–3997 (2014).
doi: 10.1021/pr500128t
Comunale, M. A. et al. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One. 5, e12419 (2010).
doi: 10.1371/journal.pone.0012419
Kuno, A. et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 3, 1065 (2013).
doi: 10.1038/srep01065
Kamada, Y. et al. Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol. Commun. 1, 780–791 (2017).
doi: 10.1002/hep4.1080
Kobayashi, T. et al. Quantifying protein-specific N-glycome profiles by focused protein- and immunoprecipitation-glycomics. J. Proteome. Res, https://doi.org/10.1021/acs.jproteome.9b00232 .
doi: 10.1021/acs.jproteome.9b00232
Greene, C. M. et al. α1-Antitrypsin deficiency. Nat. Rev. Dis. Primers. 2, 16051 (2016).
doi: 10.1038/nrdp.2016.51
Tilg, H., Vannier, E., Vachino, G., Dinarello, C. A. & Mier, J. W. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178, 1629–1636 (1993).
doi: 10.1084/jem.178.5.1629
Bucurenci, N., Blake, D. R., Chidwick, K. & Winyard, P. G. Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett. 300, 21–24 (1992).
doi: 10.1016/0014-5793(92)80156-B
Van Molle, W., Libert, C., Fiers, W. & Brouckaert, P. Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J. Immunol. 159, 3555–3564 (1997).
pubmed: 9317155
Pott, G. B., Chan, E. D., Dinarello, C. A. & Shapiro, L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol. 85, 886–895 (2009).
doi: 10.1189/jlb.0208145
Brinkman-Van der Linden, E. C. et al. A missense mutation in the FUT6 gene results in total absence of alpha3-fucosylation of human alpha1-acid glycoprotein. J. Biol. Chem. 271, 14492–14495 (1996).
doi: 10.1074/jbc.271.24.14492
Bassagañas, S. et al. Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines. Cytokine. 75, 197–206 (2015).
doi: 10.1016/j.cyto.2015.04.006
Bertola, A. et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 5, e13577 (2010).
doi: 10.1371/journal.pone.0013577
Feldstein, A. E. et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 50, 1072–1078 (2009).
doi: 10.1002/hep.23050
Hagström, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265–1273 (2017).
doi: 10.1016/j.jhep.2017.07.027
Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 65, 1557–1565 (2017).
doi: 10.1002/hep.29085
Angulo, P. et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149, 389–397 (2015).
doi: 10.1053/j.gastro.2015.04.043
Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59, 550–556 (2013).
doi: 10.1016/j.jhep.2013.04.027
Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129, 113–121 (2005).
doi: 10.1053/j.gastro.2005.04.014
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41, 1313–1321 (2005).
doi: 10.1002/hep.20701
Kleiner, D. E. et al. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Semin. Liver Dis. 32, 3–13 (2012).
doi: 10.1055/s-0032-1306421
Bedossa, P. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 56, 1751–1759 (2012).
doi: 10.1002/hep.25889
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. & Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467–2474 (1999).
doi: 10.1111/j.1572-0241.1999.01377.x
Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104–1112 (2009).
doi: 10.1016/j.cgh.2009.05.033
Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 38, 518–526 (2003).
doi: 10.1053/jhep.2003.50346
Fujitani, N. et al. Total cellular glycomics allows characterizing cells and streamlining the discovery process for cellular biomarkers. Proc. Natl. Acad. Sci USA 110, 2105–2110 (2013).
doi: 10.1073/pnas.1214233110
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25, 402–408 (2001).
doi: 10.1006/meth.2001.1262